2019年博士毕业于英国伦敦大学学院（University College London，UCL）有机化学专业，导师Jim Anderson教授（英国皇家化学会会士）。期间受国家留学基金委-UCL联合奖学金资助，并于2016年，2018年获UCL化学系“Bader奖”和“Davies奖”。

2020年入职中国药科大学工学院，现为生物医学工程与诊断药学系副教授，兴药副研究员。2021年获江苏省“双创博士”资助。

招生方向：制药工程学（学硕）|生物与医药（制药工程与工艺）（专硕）

1.活性天然产物的模块化制备与药理活性评价

（基础研究，通过有机合成方法学开发，实现基于关键药效团导向的多样性分子库构建，通过活性筛选（如抗肿瘤、抗阿尔茨海默病）挖掘苗头化合物，促进新药发现和新机制研究）

2.复杂药物的全合成与工艺开发

（应用研究，瞄准附加值高，结构复杂的手性药物，通过新型工艺开发，解决生产工艺中的：1，卡脖子技术问题（新技术引入、手性控制、异构体分离）和2，自主知识产权布局。）

1.国家自然科学基金青年项目，2021-2023，主持

2.中央高校基本科研业务经费重点项目，2022-2023，主持

3.专利申请权转让（CN202211224064.0），2022，主持

4.校企合作项目（伊洛前列腺素类似物的小试工艺开发），2024，主持

(1) Qing Li, Yuting Zhao, Xinyu Zhu, Sheng Jiang, Tianyu Wang, Dawei Deng*, Xiangyu Zhang*, Traceless Nitro Group Directing Strategy: Modular Syntheses of the Scaffolds of Polycyclic Alkaloids Org. Lett. 2025, doi: 10.1021/acs.orglett.5c02174  (封面文章)

(2) Zhihao Qi, Yao Cheng, Kaizhen Wang, Shi Cai, Xiang Ni, Tianyu Wang, Kuojun Zhang, Sheng Jiang*, Yibei Xiao*, and Xiangyu Zhang*, Discovery, Synthesis, and Activity Evaluation of Novel Small-Molecule Inhibitors Targeting VISTA for Cancer Immunotherapy J. Med. Chem. 2025, 68, 5222-5237.

(3) Xiangyu Zhang; Vallesamidine and schizozygane alkaloids: rearranged monoterpene indole alkaloids and synthetic endeavours, Nat. Prod. Rep. 2024, 41, 784.

(4) Kaizhen Wang, Shi Cai, Yao Cheng, Zhihao Qi, Xiang Ni, Kuojun Zhang, Yibei Xiao,* Xiangyu Zhang,* Tianyu Wang* Discovery of Benzo[d]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway J. Med. Chem. 2024, 67, 18526–18548.

(5) Tianyu Wang; Kaizhen Wang; Yu Zhang; Kuojun Zhang; Shi Cai; Sheng Jiang*; Yibei Xiao*; Xiangyu Zhang*; Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA).  J. Med. Chem. 2023, 66, 11881-11892.

(6) Kaizhen Wang1; Xiangyu Zhang1; Yao Cheng1; Zhihao Qi1; Ke Ye; Kuojun Zhang; Sheng Jiang; Yi Liu; Yibei Xiao; Tianyu Wang; Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy.  J. Med. Chem. 2023, 66, 16807-16827.

(7) Kaizhen Wang1; Ke Ye1; Xiangyu Zhang1; Tianyu Wang; Zhihao Qi; Youjun Wang; Sheng Jiang*and Kuojun Zhang*; Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer. J. Med. Chem. 2023, 66, 1027.

(8) Kuojun Zhang; Tianyu Wang; Maotian Li; Mu Liu; He Tang; Lin Wang; Ke Ye; Jiamei Yang; Sheng Jiang; Yibei Xiao; Youhua Xie; Meiling Lu; Xiangyu Zhang; Discovery of quinazolin-4-onebased non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro).  Eur. J. Med. Chem. 2023, 257: 115487. 

(9) Shi Cai; Kaizhen Wang; Zhihao Qi; Ke Ye; Xinyuan Zhou; Sheng Jiang; Kuojun Zhang*; Xiangyu Zhang*; Tianyu Wang*, Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold.  Eur. J. Med. Chem. 2023, 256, 115468.

(10) Xiangyu Zhang; James C. Anderson, A Divergent Synthetic Route to the Vallesamidine and Schizozygine Alkaloids: Total Synthesis of (+)-Vallesamidine and (+)-14,15-Dehydrostrempeliopine., Angew. Chem. Int. Ed. 2019, 58, 18040-18045 [Synfact 2025, 21, 763亮点文章收录]